| Code | CSB-RA001950MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GSK933776, targeting amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays crucial roles in neuronal development, synaptic plasticity, and cell adhesion. The protein undergoes sequential proteolytic cleavage by β-secretase and γ-secretase to generate amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Dysregulation of APP processing is central to the pathogenesis of Alzheimer's disease and other neurodegenerative disorders, making it a critical target for understanding disease mechanisms and exploring therapeutic interventions.
GSK933776 is a humanized monoclonal antibody originally developed to target the N-terminal region of APP, designed to modulate APP processing and reduce amyloid-beta production. This biosimilar antibody provides researchers with a valuable tool for investigating APP biology, studying amyloid cascade pathways, and evaluating potential therapeutic strategies in neurodegenerative disease models. It supports research in neurodegeneration, protein processing mechanisms, and Alzheimer's disease pathology.
There are currently no reviews for this product.